ZA965650B - Treatment of arterloscierosis and xanthoma - Google Patents
Treatment of arterloscierosis and xanthomaInfo
- Publication number
- ZA965650B ZA965650B ZA965650A ZA965650A ZA965650B ZA 965650 B ZA965650 B ZA 965650B ZA 965650 A ZA965650 A ZA 965650A ZA 965650 A ZA965650 A ZA 965650A ZA 965650 B ZA965650 B ZA 965650B
- Authority
- ZA
- South Africa
- Prior art keywords
- dione
- ylmethoxy
- methoxy
- xanthoma
- benzylüthiazolidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Glass Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16729195 | 1995-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA965650B true ZA965650B (en) | 1997-01-27 |
Family
ID=15847039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA965650A ZA965650B (en) | 1995-07-03 | 1996-07-03 | Treatment of arterloscierosis and xanthoma |
Country Status (20)
Country | Link |
---|---|
US (2) | US5798375A (ko) |
EP (1) | EP0753298B2 (ko) |
KR (1) | KR100424124B1 (ko) |
CN (1) | CN1089584C (ko) |
AT (1) | ATE209046T1 (ko) |
AU (1) | AU706628B2 (ko) |
CA (1) | CA2180296C (ko) |
CZ (1) | CZ286832B6 (ko) |
DE (1) | DE69617116T3 (ko) |
DK (1) | DK0753298T3 (ko) |
ES (1) | ES2165474T5 (ko) |
HK (1) | HK1011928A1 (ko) |
HU (1) | HUP9601808A3 (ko) |
IL (1) | IL118778A (ko) |
NO (1) | NO318765B1 (ko) |
NZ (1) | NZ286920A (ko) |
PT (1) | PT753298E (ko) |
RU (1) | RU2158607C2 (ko) |
TW (1) | TW474809B (ko) |
ZA (1) | ZA965650B (ko) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
WO1998025598A2 (en) * | 1996-12-11 | 1998-06-18 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumour cell growth |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
SI1009400T1 (en) * | 1997-08-29 | 2005-04-30 | Pfizer Inc. | Combination therapy comprising atorvastatin and an antihypertensive agent |
GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
IL135537A (en) * | 1997-10-08 | 2006-08-20 | Daiichi Sankyo Co Ltd | Melted heterocyclic compounds |
DE69834508T2 (de) * | 1997-11-19 | 2006-11-23 | Takeda Pharmaceutical Co. Ltd. | Apoptoseinhibitoren |
US20030105154A1 (en) | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
EP1087963B1 (en) | 1998-06-19 | 2004-08-25 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
US7045519B2 (en) * | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
US7141602B2 (en) * | 1998-09-18 | 2006-11-28 | Lek Pharmaceuticals D.D. | Process for obtaining HMG-CoA reductase inhibitors of high purity |
US6326396B1 (en) | 1998-11-20 | 2001-12-04 | Alteon, Inc. | Glucose and lipid lowering compounds |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
TWI284533B (en) | 1999-05-24 | 2007-08-01 | Sankyo Co | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant |
US6465011B2 (en) | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6372251B2 (en) * | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
DZ3218A1 (fr) | 1999-10-11 | 2001-04-19 | Pfizer | Pyrimidine-7-ones 5-(2-substitutees-5-heterocyclylsulphonylpyride-3-yl)-dihydropyrazolo[4,3-d] servant d'inhibiteurs de la phosphodiesterase |
EP1254667A4 (en) * | 2000-02-10 | 2003-03-12 | Takeda Chemical Industries Ltd | MEDICINE COMPRISING A COMBINATION |
USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
WO2001076566A1 (en) * | 2000-04-10 | 2001-10-18 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
FR2807944B1 (fr) * | 2000-04-25 | 2003-06-13 | Solvay Pharma | Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament |
US6806290B2 (en) | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
WO2001093860A1 (en) | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
TWI284529B (en) * | 2000-12-18 | 2007-08-01 | Sankyo Co | A composition for lowering triglyceride |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US6452014B1 (en) * | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
WO2002051396A1 (fr) * | 2000-12-26 | 2002-07-04 | Sankyo Company, Limited | Compositions pharmaceutiques contenant des derives de cyclobutene |
KR20030096294A (ko) * | 2001-03-27 | 2003-12-24 | 랜박시 래보러터리스 리미티드 | 프라바스타틴의 안정한 약학적 조성물 |
US20040077689A1 (en) * | 2001-04-25 | 2004-04-22 | Yasuo Sugiyama | Abc expression promoters |
US6486127B1 (en) | 2001-05-23 | 2002-11-26 | Insmed, Incorporated | Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof |
DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
US6987123B2 (en) | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
WO2003026643A2 (en) * | 2001-09-21 | 2003-04-03 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
EP1601669B1 (en) | 2003-03-07 | 2008-12-24 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
ES2421520T3 (es) * | 2003-04-28 | 2013-09-03 | Daiichi Sankyo Co Ltd | Potenciador de la producción de adiponectina |
US7772272B2 (en) * | 2003-04-28 | 2010-08-10 | Daiichi Sankyo Company, Limited | Method for enhancing glucose uptake into warm-blooded animal adipocytes |
NZ543741A (en) | 2003-05-30 | 2009-10-30 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as HMG-Co inhibitors |
WO2005000299A1 (en) * | 2003-06-27 | 2005-01-06 | Dr. Reddy's Research Foundation | Compositions comprising balaglitazone and further antidiabetic compounds |
US6978908B2 (en) * | 2003-09-15 | 2005-12-27 | Gerber Products Company | Drinking vessel with adjustable handles |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
JP2005200419A (ja) * | 2004-01-16 | 2005-07-28 | National Health Research Inst | 癌治療法 |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
EP1685841A1 (en) * | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
DE102005045518A1 (de) * | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
US8026377B2 (en) | 2005-11-08 | 2011-09-27 | Ranbaxy Laboratories, Limited | Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt |
EP1984026B1 (en) * | 2006-01-30 | 2013-05-01 | Ben David Bryson Israel | Compositions treating cardiovascular, cerebrovascular and other vascular disease patients |
CN101454005B (zh) | 2006-03-16 | 2013-01-02 | 新陈代谢解决方案开发公司 | 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物 |
CA2646149A1 (en) * | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids |
US20080051417A1 (en) * | 2006-07-18 | 2008-02-28 | Yochai Birnbaum | Uses of selective cyclooxygenase-1 inhibitors |
DE102006051625A1 (de) * | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
US8304441B2 (en) | 2007-09-14 | 2012-11-06 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic diseases |
ES2398313T3 (es) | 2007-09-14 | 2013-03-15 | Metabolic Solutions Development Company Llc | 5-(4-(2-(3-metoxifenil)-2-oxoetoxi)bencil)tiazolidin-2,4-diona para uso en el tratamiento de la diabetes |
WO2011084453A1 (en) | 2009-12-15 | 2011-07-14 | Metabolic Solutions Development Company | Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
AU2016348638A1 (en) | 2015-11-06 | 2018-06-07 | Gemphire Therapeutics Inc. | Gemcabene combinations for the treatment of cardiovascular disease |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
AU535944B2 (en) * | 1979-06-15 | 1984-04-12 | Merck & Co., Inc. | Hypocholestermic fermentation products from aspergillus |
AU548996B2 (en) * | 1980-02-04 | 1986-01-09 | Merck & Co., Inc. | Tetrahydro-2h-pyran-2-one derivatives |
DK149080C (da) * | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US5169857A (en) * | 1988-01-20 | 1992-12-08 | Bayer Aktiengesellschaft | 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis |
JPS58118577A (ja) * | 1982-01-07 | 1983-07-14 | Takeda Chem Ind Ltd | チアゾリジン誘導体 |
US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
HU210339B (en) * | 1985-05-21 | 1995-03-28 | Pfizer | Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect |
US4873255A (en) * | 1987-02-04 | 1989-10-10 | Sankyo Company Limited | Thiazolidinone derivatives, their preparation and their use |
FI91869C (fi) * | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
EP0295828A1 (en) * | 1987-06-13 | 1988-12-21 | Beecham Group Plc | Novel compounds |
US5260445A (en) * | 1987-09-04 | 1993-11-09 | Beecham Group P.L.C. | 2,4-thiazolidinediones |
US5194443A (en) * | 1987-09-04 | 1993-03-16 | Beecham Group P.L.C. | Compounds |
EP0306228B1 (en) * | 1987-09-04 | 1999-11-17 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
US5232925A (en) * | 1987-09-04 | 1993-08-03 | Beecham Group P.L.C. | Compounds |
NO177005C (no) * | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
WO1989008650A1 (en) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
MX15171A (es) * | 1988-03-08 | 1993-05-01 | Pfizer | Derivados de tiazolidinodiona hipoglicemicos |
US5120754A (en) * | 1988-03-08 | 1992-06-09 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
US5223522A (en) * | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
US4897405A (en) * | 1989-04-21 | 1990-01-30 | American Home Products Corporation | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
GB8919434D0 (en) * | 1989-08-25 | 1989-10-11 | Beecham Group Plc | Novel compounds |
WO1991007107A1 (en) * | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
JPH0469383A (ja) * | 1990-07-06 | 1992-03-04 | Yamanouchi Pharmaceut Co Ltd | 置換チアゾリジン誘導体 |
GB9017218D0 (en) * | 1990-08-06 | 1990-09-19 | Beecham Group Plc | Novel compounds |
JPH05202042A (ja) * | 1992-01-24 | 1993-08-10 | Sankyo Co Ltd | 糖尿病性合併症治療剤 |
CA2118706A1 (en) * | 1992-07-13 | 1994-01-20 | Saizo Shibata | Novel thiazolidinedione compounds and use thereof |
JPH0741423A (ja) * | 1993-02-24 | 1995-02-10 | Sankyo Co Ltd | 動脈硬化症治療剤 |
US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
IL113313A (en) * | 1994-04-11 | 1999-09-22 | Sankyo Co | Heterocyclic compounds and pharmaceutical compositions containing the same |
CA2159938A1 (en) * | 1994-10-07 | 1996-04-08 | Hiroaki Yanagisawa | Oxime derivatives, their preparation and their therapeutic use |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
KR19990087076A (ko) * | 1996-04-05 | 1999-12-15 | 다께다 구니오 | 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물 |
ATE355840T1 (de) * | 1997-06-18 | 2007-03-15 | Smithkline Beecham Plc | Behandlung der diabetes mit thiazolidindione und metformin |
-
1996
- 1996-07-02 NO NO19962784A patent/NO318765B1/no not_active IP Right Cessation
- 1996-07-02 AU AU56261/96A patent/AU706628B2/en not_active Ceased
- 1996-07-02 TW TW085107984A patent/TW474809B/zh active
- 1996-07-02 CA CA002180296A patent/CA2180296C/en not_active Expired - Fee Related
- 1996-07-02 NZ NZ286920A patent/NZ286920A/en not_active IP Right Cessation
- 1996-07-02 US US08/676,090 patent/US5798375A/en not_active Expired - Lifetime
- 1996-07-02 IL IL11877896A patent/IL118778A/xx not_active IP Right Cessation
- 1996-07-02 RU RU96112769/14A patent/RU2158607C2/ru not_active IP Right Cessation
- 1996-07-02 HU HU9601808A patent/HUP9601808A3/hu unknown
- 1996-07-03 DE DE69617116T patent/DE69617116T3/de not_active Expired - Lifetime
- 1996-07-03 KR KR1019960026891A patent/KR100424124B1/ko not_active IP Right Cessation
- 1996-07-03 EP EP96304924A patent/EP0753298B2/en not_active Expired - Lifetime
- 1996-07-03 ZA ZA965650A patent/ZA965650B/xx unknown
- 1996-07-03 CZ CZ19961982A patent/CZ286832B6/cs not_active IP Right Cessation
- 1996-07-03 PT PT96304924T patent/PT753298E/pt unknown
- 1996-07-03 ES ES96304924T patent/ES2165474T5/es not_active Expired - Lifetime
- 1996-07-03 AT AT96304924T patent/ATE209046T1/de not_active IP Right Cessation
- 1996-07-03 DK DK96304924T patent/DK0753298T3/da active
- 1996-07-03 CN CN96112170A patent/CN1089584C/zh not_active Expired - Fee Related
-
1998
- 1998-04-16 US US09/061,446 patent/US6159997A/en not_active Expired - Lifetime
- 1998-12-10 HK HK98113080A patent/HK1011928A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HUP9601808A3 (en) | 2000-06-28 |
IL118778A0 (en) | 1996-10-31 |
EP0753298B2 (en) | 2011-02-16 |
KR970005307A (ko) | 1997-02-19 |
ES2165474T3 (es) | 2002-03-16 |
CZ286832B6 (en) | 2000-07-12 |
CN1089584C (zh) | 2002-08-28 |
DK0753298T3 (da) | 2002-05-21 |
DE69617116T3 (de) | 2011-10-06 |
HK1011928A1 (en) | 1999-07-23 |
ATE209046T1 (de) | 2001-12-15 |
EP0753298A1 (en) | 1997-01-15 |
PT753298E (pt) | 2002-03-28 |
NZ286920A (en) | 1997-06-24 |
TW474809B (en) | 2002-02-01 |
HUP9601808A2 (en) | 1997-04-28 |
CZ198296A3 (en) | 1997-01-15 |
CA2180296A1 (en) | 1997-01-04 |
RU2158607C2 (ru) | 2000-11-10 |
IL118778A (en) | 1999-07-14 |
NO962784L (no) | 1997-01-06 |
ES2165474T5 (es) | 2011-06-08 |
US5798375A (en) | 1998-08-25 |
CN1148492A (zh) | 1997-04-30 |
AU5626196A (en) | 1997-01-16 |
CA2180296C (en) | 2007-01-09 |
DE69617116T2 (de) | 2002-08-29 |
EP0753298B1 (en) | 2001-11-21 |
NO318765B1 (no) | 2005-05-02 |
US6159997A (en) | 2000-12-12 |
KR100424124B1 (ko) | 2004-06-26 |
AU706628B2 (en) | 1999-06-17 |
NO962784D0 (no) | 1996-07-02 |
DE69617116D1 (de) | 2002-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA965650B (en) | Treatment of arterloscierosis and xanthoma | |
RU96112769A (ru) | Лечение артериосклероза и ксантомы | |
CA2273298A1 (en) | Product and method for the treatment of hyperlipidemia | |
AU6959898A (en) | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies | |
AU4614793A (en) | Liquid-permeable topsheet for body fluid absorptive goods | |
FI945457A (fi) | Testosteronin 5alfa-reduktaasiaktiviteetin inhibiittorit | |
EE04356B1 (et) | aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis | |
AU5733796A (en) | High-dose chromic tripicolinate for the treatment of type ii diabetes | |
AU2058992A (en) | HMG-COA reductase inhibitors | |
HK1003051A1 (en) | Treatment and prophylaxis of pancreatitis | |
AU4705193A (en) | Medicaments for the treatment or prevention of elevated intraocular pressure | |
MY118381A (en) | Statin-carboxyalkylether combinations | |
AU4694999A (en) | Use of thiazolidinedione derivatives for the treatment or prevention of cataracts | |
AU1680292A (en) | Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen | |
WO2001035979A3 (en) | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity | |
AU5270693A (en) | Pharmaceutical composition for preventing or treating arteriosclerosis | |
ZA9510970B (en) | Synergistic combinations of 2-(thiocyanomethylthio) benzothiazole and thiophanate compounds useful as fungicides | |
TH27628B (th) | การรักษาโรคผนังเส้นเลือกแดงหนาแข็งและแซนโธมา | |
BR9813539A (pt) | Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas | |
DE59813136D1 (de) | Verwendung von Thiaminen zur Herstellung eines Arzneimittels zur Prophylaxe und zur Therapie der diabetischen Retinopathie und der diabetischen Nephropathie | |
MX9602577A (es) | Tratamiento de arterioesclerosis y xantoma. | |
CO5611117A2 (es) | Combinacion de compuestos organicos | |
NO932874D0 (no) | Anvendelse av lacidipin for behandling av arteriosklerose | |
AU5970294A (en) | Agents for the prevention and treatment of lesch-nyhan syndrome | |
WO2000007582A3 (en) | Use of thiazolidinedione derivatives for the treatment or prevention of cataracts |